Online pharmacy – Scuba Dive Talks http://scubadivetalks.com/ Wed, 23 Nov 2022 14:07:36 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://scubadivetalks.com/wp-content/uploads/2021/07/scuba.png Online pharmacy – Scuba Dive Talks http://scubadivetalks.com/ 32 32 Global Pharmacogenomics Market Analysis Report 2022: A Market of Over $10.5 Billion by 2026 https://scubadivetalks.com/global-pharmacogenomics-market-analysis-report-2022-a-market-of-over-10-5-billion-by-2026/ Wed, 23 Nov 2022 13:45:00 +0000 https://scubadivetalks.com/global-pharmacogenomics-market-analysis-report-2022-a-market-of-over-10-5-billion-by-2026/ DUBLIN, November 23, 2022 /PRNewswire/ — The Pharmacogenomics Global Market Report 2022 has been added to from ResearchAndMarkets.com offer. Research_and_Markets_Logo The global pharmacogenomics market is expected to grow from $6.64 billion in 2021 for $7.23 billion in 2022 at a compound annual growth rate (CAGR) of 8.93%. The Pharmacogenomics Market is Expected to Reach $10.51 […]]]>

DUBLIN, November 23, 2022 /PRNewswire/ — The Pharmacogenomics Global Market Report 2022 has been added to from ResearchAndMarkets.com offer.

Research_and_Markets_Logo

The global pharmacogenomics market is expected to grow from $6.64 billion in 2021 for $7.23 billion in 2022 at a compound annual growth rate (CAGR) of 8.93%. The Pharmacogenomics Market is Expected to Reach $10.51 billion in 2026 at a compound annual growth rate (CAGR) of 9.80%.

The growing demand for precision medicine is driving the demand for the pharmacogenomics market. Precision medicine is a medical model that offers personalization of healthcare, with medical decisions, treatments, practices, or products tailored to a subset of patients rather than a single model for all drugs.

There is a growing demand for precision medicine as it is the most advanced in oncology, having broader and exciting applications beyond oncology and late-stage diseases such as rare and genetic diseases. The main goal of precision medicine is to integrate genetic and environmental information about particular diseases and/or their responses to particular treatments.

For example, according to the article published on Linchpinseo in March 2022, the growing demand for investment in precision medicine from major pharmaceutical companies will see a one-third increase over the next five years. Furthermore, in the UNITED STATES, 30 million people with type 2 diabetes are diagnosed and treated where precision medicine provides individualized treatment and will recalibrate current treatment practices. Hence, the growing demand for precision medicine will drive the pharmacogenomics market.

Technological advancement is a key trend gaining popularity in the pharmacogenomics market. Drug manufacturers are focusing on various approaches to pharmacogenomic analysis to provide cost-effective solutions for screening known polymorphisms and discovering new variants.

The countries covered in the Pharmacogenomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South KoreaUK and UNITED STATES.

Report scope

  • The pharmacogenomic marker consists of the sale of pharmacogenomic tests by entities (organizations, individual companies and partnerships) which refer to a specific medical treatment to each person or group of people. Pharmacogenomics is a field of research that studies how a patient’s genes affect and how they respond to drugs.

  • The long-term goal of pharmacogenomics is to help physicians select the most appropriate drugs and doses for each individual. Pharmacogenomics will be used to create personalized medicines to treat various health conditions, including cardiovascular disease, Alzheimer’s disease, cancer and asthma.

  • The major technologies used in the pharmacogenomics market are next generation sequencing (NGS), polymerase chain reaction, gel electrophoresis, mass spectrometry, microarrays, and other technologies. NGS is a massively parallel sequencing technology that offers ultra-high throughput, scalability, and speed.

  • The technology is used to determine the order of nucleotides in entire genomes or specific regions of DNA or RNA. Applications of pharmacogenomics include neurology, drug discovery, oncology, cardiology, pain management, and other applications. The end user included hospitals and clinics, research institutes and academic institutes.

  • North America was the largest region in the Pharmacogenomics Market in 2021. Asia Pacific is expected to be the fastest growing region during the forecast period. Regions covered in the Pharmacogenomics market report are Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Key players in the Pharmacogenomics market are

  • Abbott Laboratories

  • Astra Zeneca plc

  • Becton Dickinson and Company

  • Bayer AG

  • F Hoffmann-La Roche AG

  • Illumina Inc.

  • GlaxoSmithKline plc

  • Merck KGaA

  • Myriad Genetics Inc

  • Thermo Fisher Scientific Inc.

  • OPKO Health Inc

  • Assurex Health Inc

  • Empire Genomics LLC

  • Future Science Group

  • Pathway Genomics Corporation

Main topics covered:

1. Summary

2. Characteristics of Pharmacogenomics Market

3. Pharmacogenomics Market Trends and Strategies

4. Impact of COVID-19 on pharmacogenomics

5. Pharmacogenomics Market Size and Growth
5.1. Global Pharmacogenomics Historic Market, 2016-2021, USD Billion
5.1.1. Market Drivers
5.1.2. Market Constraints
5.2. Global Pharmacogenomics Forecast Market, 2021-2026F, 2031F, Billion USD
5.2.1. Market Drivers
5.2.2. Market Constraints

6. Pharmacogenomics Market Segmentation
6.1. Global Pharmacogenomics Market, Segmentation by Technology, History and Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion

6.2. Global Pharmacogenomics Market, Segmentation by Distribution Channel, History and Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion

  • Hospital pharmacy

  • Online pharmacy

  • Retail pharmacy

6.3. Global Pharmacogenomics Market, Segmentation by Application, History and Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion

  • Neurology

  • drug discovery

  • Oncology

  • Cardiology

  • pain management

  • Other Apps

6.4. Global Pharmacogenomics Market, Segmentation by End User, History and Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion

  • Hospitals And Clinics

  • Research institutions

  • University institutes

7. Regional and Country Analysis of Pharmacogenomics Market
7.1. Global Pharmacogenomics Market, Split by Region, Historical & Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion
7.2. Global Pharmacogenomics Market, Split by Country, Historical & Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion

For more information about this report visit https://www.researchandmarkets.com/r/pmvrwf

Media Contact:

Research and Markets
Laura Woodsenior
press@researchandmarkets.com

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Quote

Quote

View original content: https://www.prnewswire.com/news-releases/global-pharmacogenomics-market-analysis-report-2022-a-10-5-billion-market-by-2026—long-term – forecast-until-2031–301686014.html

SOURCE Research and Markets

]]>
Counterfeit Adderall Reported in Pennsylvania and Other Shortage States https://scubadivetalks.com/counterfeit-adderall-reported-in-pennsylvania-and-other-shortage-states/ Mon, 21 Nov 2022 03:03:00 +0000 https://scubadivetalks.com/counterfeit-adderall-reported-in-pennsylvania-and-other-shortage-states/ PENNSYLVANIA, USA — A nationwide shortage of prescription mixed amphetamine salts, more commonly known by their brand-name version Adderall, has people finding other ways to get the drug. “There are a lot of illicit uses for Adderall, so the demand is there,” said Erik Hefti, executive director and assistant professor of pharmaceutical sciences at the […]]]>

PENNSYLVANIA, USA — A nationwide shortage of prescription mixed amphetamine salts, more commonly known by their brand-name version Adderall, has people finding other ways to get the drug.

“There are a lot of illicit uses for Adderall, so the demand is there,” said Erik Hefti, executive director and assistant professor of pharmaceutical sciences at the University of Harrisburg. “And not only that, it’s heavily regulated, so it’s hard to get a legit Adderall.”

Social media and the internet have become popular destinations for finding counterfeits.

“The big concern here is that if there’s a shortage, Americans will go online and try to source Adderall themselves,” said Shabbir Imber Safdar of the Partnership for Safe Medicines. “96% of online pharmacies that you find through search engines are operating illegally.”

Hefti said easy access to counterfeit versions of the drug poses a security risk.

“Counterfeit drugs have no quality control per se,” Hefti said. “So you really don’t know what you’re taking and it can be very dangerous in different ways.”

According to a report by the Partnership for Safe Medicines, counterfeit cases of Adderall in more than 25 states, including Pennsylvania, involve pills containing methamphetamine, fentanyl and other unknown substances.

One way to tell if a pill is legit is to identify the drug and the company that made it. A telltale sign of counterfeit drugs doesn’t have markings, although in some cases they look like the real thing, like these pictures from the Drug Enforcement Administration.

“These things look so good even a pharmacist couldn’t tell the difference,” Safdar said.

Bottom line, Hefti said it’s important to get your prescription from a reputable source.

“If you get Adderall from anywhere other than a pharmacy or a medical professional, you run a huge risk that it is indeed counterfeit.”

Download the FOX43 News app.

]]>
Medicine shortages: more than a million vials of medicine are due to arrive https://scubadivetalks.com/medicine-shortages-more-than-a-million-vials-of-medicine-are-due-to-arrive/ Fri, 18 Nov 2022 15:33:00 +0000 https://scubadivetalks.com/medicine-shortages-more-than-a-million-vials-of-medicine-are-due-to-arrive/ More than one million bottles of children’s painkillers will arrive in Canada starting next week, the federal government said in an update on drug shortages plaguing the country. Chief medical adviser Dr. Supriya Sharma told reporters on Friday that Health Canada was exploring “every lever” at its disposal to remedy the situation and understand that […]]]>

More than one million bottles of children’s painkillers will arrive in Canada starting next week, the federal government said in an update on drug shortages plaguing the country.

Chief medical adviser Dr. Supriya Sharma told reporters on Friday that Health Canada was exploring “every lever” at its disposal to remedy the situation and understand that this is a “very difficult” situation for parents and health care providers.

“As drug shortages continue to dominate the headlines, we are working tirelessly behind the scenes to end the shortages. It will take time, but things will improve as we begin to see the results of increased production of Canadian acetaminophen and ibuprofen products supplemented by the flow of foreign products entering the country,” he said. she declared.

The supply will be donated to hospitals, community pharmacies and retailers and will start appearing on store shelves early next week, Sharma said. Products included in the newly purchased supply include children’s liquid ibuprofen and liquid acetaminophen.

Drug shortages in Canada began as early as last spring, CTVNews.ca reported. There are hundreds of drugs that are running out or are now entirely out of stock, and the problem extends beyond children’s drugs.

Three major viruses currently circulating – RSV, influenza and COVID-19 – are leading to crowded hospitals and overcrowded pediatric intensive care units, especially in Ontario.

Health Canada met with stakeholders including manufacturers, retailers and healthcare professionals on a weekly basis to “share information and strategies,” Sharma said.

She also said that procurement proposals are also being evaluated and that all proposals received will be reviewed to ensure they meet Health Canada’s standards for efficacy and safety. So far, three proposals for importing foreign drugs have been approved and the supply is now entering the country.

OTTAWA UNDER PRESSURE TO SOLVE SHORTAGE

According to the agency, 800 drugs are missing and 23 are at critically low levels.

Amid the many diseases circulating, Ottawa has been under increased pressure from the provinces and the federal opposition for the past few weeks to act on drug shortages. Conservatives have urged the federal government to allow the sale of drugs with foreign-language labels.

Health Canada said this week that with respect to the incoming supply, “all information relating to cautions and warnings, dosage instructions, ingredients and other important details will be available in English and French. French to ensure that parents and caregivers clearly understand what medicine they are using and how to give their children.

Since the drug importation began, hospitals are now seeing a “fairly stable” supply of painkillers for children, as the imported products have already been supplied, Sharma told reporters. Bilingual product labeling has not slowed access, she said.

When asked why Health Canada had not taken action earlier in the year to import drugs as shortages emerged from the spring, Sharma said there had been an initial consultation with the community and stakeholders to understand demand and issues.

Manufacturers thought the increased supply could help meet demand, which seemed to alleviate the problem earlier in the year. But at the end of the summer, the government had to consider importing as demand grew, she said.

Dr. Theresa Tam, Canada’s Chief Public Health Officer, said at Friday’s press conference that COVID-19 continues to circulate across the country and RSV levels are higher than expected. for this time of year.

RSV and influenza “have a big impact on children,” Tam said. Although hospitals are seeing a high number of admissions related to these diseases, no vaccine is available. It is important to immunize children with available vaccines, such as the flu vaccine and COVID-19, she explained.

Tam also said wearing a mask and washing hands, as well as staying home when sick is critical

“One of the biggest challenges of multiple respiratory viruses circulating simultaneously is the sudden large outbreak of disease that could overwhelm the healthcare system,” she said.

Jen Belcher, an Ottawa-based pharmacist and vice-president of strategic initiatives and member relations for the Ontario Pharmacists’ Association, told CTV’s Your Morning on Friday that there are concerns that shortages don’t continue for months.

“Common antibiotics used for lung infections, ear infections…it was a real challenge for parents [to find] as they navigate respiratory virus season with very few options,” she said.

The reasons for the shortages are “complex”, which include a combination of demand, supply chain interruptions and manufacturing disruptions, she said, suggesting that drug manufacturing should be prioritized over the ‘coming.

Many drugstore shelves have been left empty, running out of children’s allergy medicine, painkillers for children and now cough and cold syrup for adults, eye drops and some oral antibiotics, according to industry experts.

Several pharmacists across Canada said the problem was only getting worse.


With files from The Canadian Press, CTV Toronto, CTV Kitchener and CTV News Senior Digital Parliamentary Reporter Rachel Aiello

]]>
Belmont Pharmacy wins Empire Award for decades of community service https://scubadivetalks.com/belmont-pharmacy-wins-empire-award-for-decades-of-community-service/ Tue, 15 Nov 2022 01:50:33 +0000 https://scubadivetalks.com/belmont-pharmacy-wins-empire-award-for-decades-of-community-service/ November 15, 2022, 1:50 a.m.Updated 4 hours ago By: News 12 Staff A Belmont pharmacy has received a very distinguished New York State award for decades of hard work and dedication to its community. In the age of CVS, Rite Aid and even online pharmacies, Mount Carmel Pharmacy continues to do what it can for […]]]>

A Belmont pharmacy has received a very distinguished New York State award for decades of hard work and dedication to its community.

In the age of CVS, Rite Aid and even online pharmacies, Mount Carmel Pharmacy continues to do what it can for its neighbors. The Paganelli family has been running the pharmacy since 1964.

“We are here seven days a week and always there for anyone who presents us with a need,” explains co-owner Armand Paganelli.

Their dedication has earned them the New York State Senate Empire Award, which is given to companies that demonstrate exemplary service to their customers and community. State Senator Gustavo Rivera presented them with the award Monday afternoon.

The Paganelli family is already looking to the future, which includes a new facility. The new Pharmacy Community Wellness Center is expected to provide health screenings, such as blood pressure checks and disease screening tests.

“The scope of this little corner is very wide. We are excited to launch this and, once again, continue to bring value to the people we serve in this community,” says Roger Paganelli.

So far, it’s unclear what their next idea is, but they seem hopeful.

“We hope to be here for many, many years serving our community, because that is what we build on,” says Armand Paganelli.

The Wellness Center is located just outside the Pharmacy on East 187th Street.

]]>
Pharmacies, patients struggling with Adderall shortage https://scubadivetalks.com/pharmacies-patients-struggling-with-adderall-shortage/ Fri, 11 Nov 2022 23:38:00 +0000 https://scubadivetalks.com/pharmacies-patients-struggling-with-adderall-shortage/ AUGUSTA, Ga. (WRDW/WAGT) – There is another supply chain issue affecting people across the country, with drastic health impacts. The FDA has declared a shortage of Adderall, but many pharmacies say the shortage began in October. Adderall is used to treat conditions such as attention deficit disorder or ADD. We spoke to a pharmacy manager […]]]>

AUGUSTA, Ga. (WRDW/WAGT) – There is another supply chain issue affecting people across the country, with drastic health impacts.

The FDA has declared a shortage of Adderall, but many pharmacies say the shortage began in October.

Adderall is used to treat conditions such as attention deficit disorder or ADD.

We spoke to a pharmacy manager at AU Health and a local mother about the effect on local patients.

“Because it’s a controlled substance, you can’t just walk into any family pharmacy or any family store and say, ‘Hey, I need Adderall, I have need a stimulant.’ You have to go to the doctor. You need to talk to your prescriber,” said Augusta University Medical Center Community Pharmacy Manager Rashad Darby.

But prescribers tell Monique Braswell…

“They say they expect to get it. We didn’t understand it. We didn’t understand it. We didn’t understand it. We didn’t understand it. That’s all they can tell us,” she said.

Darby says it could take months, and that’s too long for her daughter.

“It’s hard, it’s very, very hard, to have kids who have to take medication to manage their day, and then not have it, it’s very hard,” Braswell said.

“You are sitting here right now. You start to hear the effects of not having Adderall. Because it’s her. We are in his room. Do you hear it?

You could hear her daughter jumping upstairs. She has a son who also takes extra medications that their prescriptions can’t mix.

“A lot of medications are based on weight, on different symptoms. So what may work for person A may not work for person B. The dose may be too high, the dose may be too low. There are a lot of dangers in taking other people’s drugs, which we don’t advocate or recommend at all, especially in this circumstance where people can’t find them,” Darby said.

Braswell says advocacy at schools and pharmacies has helped them get the help her family needs.

“It’s up to you to go back to your doctor and say, ‘Hey, we can’t have this. So I need you to give me this, you know, or do this. If you don’t you’re not a lawyer, then your child is missing out,’ she said.

Darby says as a reminder, don’t go out and take another person’s Adderall or another person’s medication. It says don’t go online to find medicine on your own. Talk to your doctor.

]]>
Ontario considering letting pharmacists prescribe Paxlovid for COVID-19: Moore https://scubadivetalks.com/ontario-considering-letting-pharmacists-prescribe-paxlovid-for-covid-19-moore/ Sun, 06 Nov 2022 16:58:35 +0000 https://scubadivetalks.com/ontario-considering-letting-pharmacists-prescribe-paxlovid-for-covid-19-moore/ Ontario is considering allowing pharmacists to prescribe the COVID-19 treatment drug Paxlovid to expand access, the province’s top doctor has said. Chief Medical Officer of Health Dr Kieran Moore recently said the healthcare system will see a “triple threat” from COVID-19, a bad flu season and the resurgence of a childhood respiratory virus this fall […]]]>

Ontario is considering allowing pharmacists to prescribe the COVID-19 treatment drug Paxlovid to expand access, the province’s top doctor has said.

Chief Medical Officer of Health Dr Kieran Moore recently said the healthcare system will see a “triple threat” from COVID-19, a bad flu season and the resurgence of a childhood respiratory virus this fall and winter.

Finding ways to ensure greater availability of drugs to keep people with COVID-19 out of hospital is of particular importance for more rural communities, he said.

“I know the government is looking at the ability of pharmacists to be able to prescribe this directly after a positive test,” Moore said in an interview with The Canadian Press.

“There were concerns particularly in remote areas. Where you may not have good access to a primary care doctor, you may have access to a pharmacist. So that gap has been looked at and I think that they are actively working on this.”

Several medical officers in the province have raised the issue, Moore said.

“I think it’s a solution to increase access,” he said.

A spokesperson for Health Minister Sylvia Jones did not respond to multiple requests for comment.

Justin Bates, CEO of the Ontario Pharmacists Association, said his group is pushing for pharmacists in the province to be able to prescribe Paxlovid, as their colleagues in many other provinces already can.

“Given our experience with point-of-care testing, our knowledge of drugs – especially complex drugs like Paxlovid, where there are a lot of drug interactions – and more, I would say, a thorough consultation that is required together with patients, pharmacists are well placed to provide this turnkey solution,” he said.

Paxlovid is an antiviral medication taken by mouth within five days of the onset of symptoms.

It is recommended for people at high risk of complications from COVID-19, such as people over 70 and some immunocompromised people, especially those who have not received at least three doses of the vaccine. It can be prescribed by a primary care provider or at a COVID-19 clinical assessment center.

Having pharmacies as one more route for prescriptions will allow faster access and therefore prevent more people from being hospitalized this winter, Bates said.

“The earlier you started in five days, the better in terms of preventing symptoms and serious illnesses, which would then require you to go to the hospital or, even worse, to the intensive care unit of the hospital” , did he declare.

Paxlovid is currently “sitting on shelves,” Bates said.

“The amount of volume going through stores, anecdotally, is very low,” he said.

Moore said about 3,500 treatments of Paxlovid are currently being prescribed each week, noting that demand appears to be increasing as COVID-19 activity increases.

Ontario has already announced that starting Jan. 1, it will expand pharmacists’ prescribing powers to include drugs for minor ailments such as conjunctivitis, dermatitis and hemorrhoids.

If the government expands powers further to include not just Paxlovid but all antiviral drugs, pharmacists could also prescribe Tamiflu – which has fewer drug interactions than Paxlovid – before what is expected to be a bad flu season, Bates said.

Dr. Zain Chagla, an infectious disease specialist at St. Joseph’s Healthcare in Hamilton, said he thought it was a great idea for pharmacists to prescribe Paxlovid, saying it could save people from being hospitalized with COVID- 19.

“These are preventable health care outcomes,” he said.

“There really needs to be more of an effort to make it more accessible and pharmacies have done an amazing job helping with COVID vaccines… The major issue with Paxlovid is drug interactions and therefore, having pharmacists who prescribe it makes perfect sense”

]]>
Over-the-counter hearing aids are now available https://scubadivetalks.com/over-the-counter-hearing-aids-are-now-available/ Thu, 03 Nov 2022 21:20:23 +0000 https://scubadivetalks.com/over-the-counter-hearing-aids-are-now-available/ ALBANY, NY (NEWS10) – Hearing aids for mild to moderate hearing loss are now available without a prescription, meaning patients no longer need medical devices or even a prescription. According to experts, four out of five people likely to suffer from hearing loss are unable to solve the problem due to high costs and lack […]]]>

ALBANY, NY (NEWS10) – Hearing aids for mild to moderate hearing loss are now available without a prescription, meaning patients no longer need medical devices or even a prescription.

According to experts, four out of five people likely to suffer from hearing loss are unable to solve the problem due to high costs and lack of accessibility. Even though the devices will be available for purchase in person or online, organizations such as the Hearing Loss Association of America have been able to create guidelines for consumers.

“To enable people to identify if they have mild to moderate hearing loss, and what they could benefit from in the market, which devices will meet their needs, and how they can self-isolate or find the device that’s right for them. ,” said MaryKate Owens, President of the American Hearing Loss Association, Albany Chapter.

Dr. Debra Trees, who is an audiologist, raised concerns about whether or not a patient will be able to use the devices on their own. “They have to be aware that they will have to do self-adjustment, self-choice and self-maintenance, that’s a big part of it.”

According to officials, it will be some time before the hearing aids are available for purchase at your local pharmacy. Eileen Wood is the CDPHP’s Chief Pharmacist and believes that pharmacists will make sure to help patients from a clinical perspective.

“It’s a real opportunity for pharmacists to help patients because now they’re going to come looking for a solution,” she says. “And we’re going to be here to make sure an over-the-counter product is the right product solution.”

]]>
Pharmaceutical Waste Management in US Healthcare Facilities: US Environmental Protection Agency Funds 10-Step Plan (2022 Edition) | Mitchell, Williams, Selig, Gates & Woodyard, LLC https://scubadivetalks.com/pharmaceutical-waste-management-in-us-healthcare-facilities-us-environmental-protection-agency-funds-10-step-plan-2022-edition-mitchell-williams-selig-gates-woodyard-llc/ Mon, 31 Oct 2022 20:54:55 +0000 https://scubadivetalks.com/pharmaceutical-waste-management-in-us-healthcare-facilities-us-environmental-protection-agency-funds-10-step-plan-2022-edition-mitchell-williams-selig-gates-woodyard-llc/ Download PDF The U.S. Environmental Protection Agency (“EPA”) funded a recently released document titled: A 10-Step Blueprint for Pharmaceutical Waste Management in U.S. Healthcare Facilities (2022 Edition) (“Blueprint”) The lead author of the Blueprint is Charlotte Smith of GreatWorks, LLC. Blueprint’s 2022 edition is a later version of the document published in 2006. The document […]]]>

Download PDF

The U.S. Environmental Protection Agency (“EPA”) funded a recently released document titled:

A 10-Step Blueprint for Pharmaceutical Waste Management in U.S. Healthcare Facilities (2022 Edition) (“Blueprint”)

The lead author of the Blueprint is Charlotte Smith of GreatWorks, LLC.

Blueprint’s 2022 edition is a later version of the document published in 2006.

The document describes its main purpose as follows:

. . . provide a guide to help healthcare facilities including hospitals, surgery centers and urgent care facilities understand applicable regulations so they can develop a compliant, holistic and cost-effective pharmaceutical waste management program .

Therefore, the blueprint focuses primarily on EPA Subtitle C hazardous waste regulations as they apply to pharmaceuticals treated as hazardous waste. This issue became relevant due to the EPA’s revision of the Resource Conservation and Recovery Act (“RCRA”) regulations in 2019 by issuing the final rule titled:

Pharmaceutical Hazardous Waste Management Standards and PO75 List Amendment for Nicotine (see Federal Register Volume 84 February 2019) (“Drugs Rule”)

The Pharmaceuticals Rule added Subpart P to the RCRA Subtitle C regulations found in 40 CFR Part 266. In addition, it provided an exemption for OCT nicotine patches, gum and lozenges.

Pharmaceutical hazardous waste management is somewhat unique in that the facilities (such as pharmacies, hospitals, nursing homes, etc.) needed to meet these requirements have had relatively little exposure to the waste management system. dangerous RCRA from cradle to grave. This is markedly different from industrial and commercial facilities that have been subject to various RCRA Subtitle C requirements since the mid-1980s. Therefore, documents such as the Master Plan have been deemed essential to educate the regulated community. concerned.

The 10 steps (i.e. components) of the Blueprint include:

  • Step One: Understand which pharmaceuticals are regulated as hazardous pharmaceutical waste when discarded
  • Step two: review of standards for healthcare facilities operating under the hazardous pharmaceutical waste rule
  • Step Three: Determine Which Facilities Should Operate Under Subpart P
  • Step Four: Leadership and Current Program Review
  • Step Five: Choose the Right Suppliers
  • Step Six: Implement a Pharmaceutical Waste Management Program in the Pharmacy
  • Step Seven: Implementing a Pharmaceutical Waste Management Program in the Nursing Unit and Other Patient Care Areas
  • Step Eight: Management Responsibilities: Team Management, Developing Policies and Procedures, and Improving Processes
  • Step Nine: Training Programs – Program Relaunch and Online Training
  • Step Ten: RCRA Generator Category for Facilities Operating Under Subpart P

Annexes to the Master Plan include:

  • Appendix A. Links to Code of Federal Regulations (40 CFR) for Subpart P
  • Appendix B. Common Acronyms
  • Appendix C. Quick Start Guide: Pharmaceutical Hazardous Waste Management — Over-the-Counter Nicotine Exemption and Subpart P
  • Appendix D. How to Assess the Toxic Characteristic Using Total Constituent Analysis Instead of TCLP—Case Study: Thimerosa
  • Appendix E. NIOSH Hazardous Drug List
  • Annex F. Step-by-step guide to notifying under Subpart P
  • Appendix G. Categories of RCRA Hazardous Waste Generators

A copy of the Blueprint can be downloaded here.

]]>
MAH Direct 2nd yr Pharmacy 2022 Merit List – Direct Link https://scubadivetalks.com/mah-direct-2nd-yr-pharmacy-2022-merit-list-direct-link/ Wed, 26 Oct 2022 18:53:19 +0000 https://scubadivetalks.com/mah-direct-2nd-yr-pharmacy-2022-merit-list-direct-link/ The merit list published today will be provisional. The posting of the final DSP merit list of candidates applying for the 2022 DSP will take place on November 1, 2022. Read more Maharashtra CET Cell Direct 2nd Year Pharmacy (DSP) Admission 2022: Maharashtra State Common Entrance Test (CET) Cell is expected to release today i.e. […]]]>

The merit list published today will be provisional. The posting of the final DSP merit list of candidates applying for the 2022 DSP will take place on November 1, 2022. Read more

Maharashtra CET Cell Direct 2nd Year Pharmacy (DSP) Admission 2022: Maharashtra State Common Entrance Test (CET) Cell is expected to release today i.e. Thursday 27th October 2022 on its official website dsp2022.mahacet.org.in Pharm and Pharm D) for the 2022-23 academic year.

Applicants should note that the DSP merit list released today will be provisional. After the Provisional Merit List is released today, applicants may raise an objection until 5:00 p.m. on October 30, 2022 if they find an error in their personal or academic information. The CET cell will publish the final DSP 22 merit list after responding to the candidates’ grievances.

Applicants should note that the final merit list of applicants applying for DSP 2022 admission will be released on November 01, 2022.

After the DSP Final Merit List is released on November 1, the admissions process will move to the next stage when applicants whose names appear in the B Pharm and D Pharm Final Merit List will be required to complete the Choice Form and college option.

Steps to Check 2022 Grade 2 Pharmacy Direct Merit List

1. Click here to access the official website: dsp2022.mahacet.org.in.
2. Click “DSP B Pharm and Pharm D Provisional Merit List” on the home page.
3. Enter your Application ID starting with DSP22 and Date of Birth.
4. Click the Submit button to verify your name and position.

Applicants should note that the CET Cell will release the Seating Matrix giving details of vacant seats at various colleges following the release of the final Pharmacy Merit List.

Applicants are required to read the Seating Matrix carefully before submitting the DSP 2022 Option Form. This is important as the allocation of seats will be based on the options submitted by applicants.

Maharashtra State Common Entrance Testing Cell (CET) had posted on its official website dsp2022.mahacet.org.in the notification, simultaneously commencing online registration for admission to the second year course Direct (DSP) full-time under postgraduate course in Pharmacy (B Pharm and Pharm D) for the year 2022-23 from October 10, 2022.

Maharashtra Direct 2nd Year Pharmacy Admission 2022 – Important Dates

Online registration of application and upload of documents required by the candidate for admission from the website (for applicants from the State of Maharashtra / All India / NRI / OCI / PIO / CIWGC / FN): 11 to 21 October 2022.

Display of the DSP 2022 provisional merit list: October 27, 2022.

Filing of grievances if applicable, for all types of Candidates: October 28 to 30, 2022.

Posting of Final DSP22 Merit List of Maharashtra/All India State Candidates on Website: 01 November 2022

Display of provisional seats by category (matrix of seats) for the first round of the CAP: to be notified later

Display of the provisional allocation of the DSP 22 CAP Round I: to be notified later

Display of provisional vacant seats for the CAP Direct 2nd year Round II: to be notified later

Display of the provisional allocation for cycle II of the CAP: to be notified later

Maharashtra MHT CET Counseling for Direct 2nd Year Admission in Pharmacy (DSP 2022) commenced after MHT CET result which was declared September 15, 2022.

Candidates who successfully complete the D Pharm (Diploma of Pharmacy) or a selected course in BSc with approved subjects are eligible for admission into Direct Admission to Second Year B Pharmacy.

Candidates can also refer to the Provisional Seating Matrix for the 2022-2023 Academic Year and the previous year’s CAP cut-off on the official website.

Meanwhile, in a prominent notification, Maharashtra’s CET cell has said final year candidates reappearing for the MSBTE summer 2022 re-examination will wait for the result to be declared.

“These applicants can complete and confirm the application form once the result is announced by the MSBTE,” CET Celle said.

For all the latest News, Views & ViewsTo download ummid.com App.

Select Language To read in Urdu, Hindi, Marathi or Arabic.

]]>
Meeting the needs of patients with rare diseases: better access to specialty pharmaceuticals, gene and cell therapies https://scubadivetalks.com/meeting-the-needs-of-patients-with-rare-diseases-better-access-to-specialty-pharmaceuticals-gene-and-cell-therapies/ Mon, 24 Oct 2022 18:14:17 +0000 https://scubadivetalks.com/meeting-the-needs-of-patients-with-rare-diseases-better-access-to-specialty-pharmaceuticals-gene-and-cell-therapies/ Anyone who puts themselves in the shoes of someone with a rare disease will experience not only the daunting prospects of deteriorating health, but also the pressure to organize effective treatment sooner and prevent morbidity and mortality. . There are 7,000 known rare diseases affecting approximately 30 million people in the United States, or about […]]]>

Anyone who puts themselves in the shoes of someone with a rare disease will experience not only the daunting prospects of deteriorating health, but also the pressure to organize effective treatment sooner and prevent morbidity and mortality. . There are 7,000 known rare diseases affecting approximately 30 million people in the United States, or about one in 10 people. The exact cause of many rare diseases remains unknown. Yet, for a significant part, the problem can be traced to mutations or changes in a single gene.

Many patients face years of difficult ‘diagnostic odyssey’ before receiving a correct diagnosis and face many obstacles to obtaining the specialty drugs or innovative gene therapies that can save their lives. The high cost of certain drugs can sometimes impede access for patients with rare diseases who often struggle to obtain affordable, adequate and accessible health care coverage. Unfortunately, over 95% of rare disease patients do not have an FDA-approved treatment for their condition. Rare diseases represent a burden for individuals and families and pose a major public health problem. The National Organization for Rare Disorders (NOTD) maintains a Rare Disease Database providing brief introductions to patients and caregivers about specific rare diseases.

Promising prospects: Specialty drugs

The increasing pace of innovation made possible by emerging scientific breakthroughs and new understanding of diseases has led to the development of new therapies. The number of new patients entering the care pipeline is steadily increasing, with some having more than one condition requiring a specialized drug.

Specialty drugs are generally defined using elements of the following criteria, identifying an agent as a specialty drug:

  • Used to treat rare or orphan diseases or complex chronic conditions
  • High contact medical condition that involves one or more of the following for the drug:
  • Requires special handling
  • Requires special administration
  • Requires special distribution or storage requirements
  • Requires special monitoring
  • Involves frequent or frequent patient care management or clinical monitoring
  • Distributed through a limited distribution network
  • High cost

Due to their high cost, specialty drugs are often prohibitively expensive and therefore add a barrier to patient access. In fact, the direct costs of specialty drugs have grown faster than gross domestic product (GDP) growth over the past decade.

These issues are contributing to the increased attention and growth of specialty pharmacy (SP) among patients and healthcare benefit payers, as well as specialty drug manufacturers who want to ensure their drugs are transparently accessible. by patients prescribed and that drug therapy is monitored for efficacy, safety, compliance and adherence to treatment.

Specialty drugs may be covered by medical or drug insurance and coverage is usually tied to where the patient receives the drug: if the patient takes a pill or injects the drug at home, it is more likely that he is covered by the pharmaceutical allowance. If the patient receives the drug in a doctor’s office, hospital, or outpatient clinic, it is more likely to be covered by the medical benefits portion of existing health insurance coverage.

One initiative that can provide substantial savings to the patient and payer is to identify an alternate care program site. These programs provide more convenience for patients and caregivers/support team members and improve opportunities for patient engagement and care in addition to reducing costs for the patient and payer.

Innovative copayment coupon programs provide an additional way for patient and payer to use manufacturer-provided funds to offset the cost of therapy. The use of these programs is already in place, improving patients’ ability to access these expensive drugs.

In the future, specialty exclusions that move specialty drugs from traditional prescription drug management to a pharmacy benefit administrator or specialty administrator are likely to continue. These arrangements provide cost savings, remove any incentive to distribute the product, and present opportunities to manage and monitor usage management programs that match the payer’s expectations.

These programs also enhance patient care coordination activities, educate patients, and provide the opportunity to improve treatment adherence. Specialized clinical support programs can also identify and mitigate barriers to continued patient adherence and monitor for side effects and adverse events, indicating the need to modify or discontinue treatment.

Going forward, specialty pharmacy networks are expected to gain wide appeal, with specialty medicines being dispensed and coordinated by identified specialty pharmacies with high contact capabilities such as personalized patient support services and advanced storage and storage capabilities. shipping. These hand-selected pharmacies serve as centers of excellence in all specialty conditions and help improve care coordination, minimize wastage by preventing excessive medication hoarding, and increase treatment adherence for results. optimal for patients.

Gene therapies

Across the industry, many envision a world where genetic blindness, severe muscular dystrophy, cancer, sickle cell disease, blood disorders and many other diseases are not just treated, but actually cured. by gene therapies. As some of the nation’s leading pharmaceutical and biotech giants ramp up product development and commercialization, what was once just a futuristic concept is becoming a reality.

Gene therapies are not just another new class of specialized drugs to treat the symptoms of a given disease – they aim to cure by correcting the underlying genetic abnormalities that cause the disease. With more than 900 Investigational New Drug (IND) applications for ongoing clinical studies of ongoing gene therapy products, and the FDA predicting that it will approve 10-20 gene therapies per year, the availability of these breakthrough drugs is growing. an emerging driver of change in the management of specialty pharmacy services.

The advent of genetic therapies that represent new options that could change the lives of the people who use them comes with high costs, as multi-million dollar drugs have arrived. In fact, a new record was set recently when the FDA approved Zynteglo, a gene therapy for beta-thalassemia, a rare disease requiring regular blood transfusions that carries a record price of $2.8 million and makes it the most expensive single-use medicine. in the United States and among the highest in the world. Others like Zolgensma which treats spinal muscular atrophy (SMA) cost $2.1 million for a single dose treatment and Luxturna for genetic blindness costs $850,000.

Stakeholders are discussing these issues, and the payment models being developed for newly approved specialty drugs and gene therapies provide a first indication of the flexibility and coordination that will be required from manufacturers, payers and decision-makers to optimize patient access.

Currently, one of the potential solutions to payor coverage is a loan-based assistance program, which converts the high initial cost of ultra-expensive therapies into a loan repayable over time in small, predictable payments. This opportunity protects payers against treatment failures using drug product guarantee and/or value or risk-based agreement, provides a mechanism for patient mobility transfers from one payer to another, reduces the need of stop-loss or reinsurance and improves patients’ access to ultra-expensive therapies.

Over time, the gene and cell therapy market is expected to venture beyond targeting rare diseases alone, with leading MS innovators introducing solutions that address patient health outcome monitoring and affordability concerns. .

Photo: cagkansayin, Getty Images

]]>